LabCorp's Drug Development Business, Covance, Acquires GlobalCare
LabCorp recently announced the company’s drug development business, Covance, has acquired GlobalCare, a globally recognized industry leader in patient-centric decentralized clinical trials support services.
This acquisition will expand Covance’s decentralized clinical trials capabilities globally, enabling recruitment and increasing access to trials. It will also benefit GlobalCare’s current and future customers by providing access to needed resources and technology to scale services to meet growing industry needs.
For more information, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.
